Valeant Pharma (VRX) Won't File 10-K Within 15-Day Extension Period
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Valeant (VRX) PT Cut to $40 at Canaccord Genuity
March 16, 2016 9:40 AM EDTCanaccord Genuity analyst Neil Maruok reiterated a Hold rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $40.00 (from $75.00).
Maruok commented, "guidance was even lower than our base-case scenario and we believe has begun to erode investor confidence in Valeants underlying business. We believe that the implementation of the partnership with Walgreens,... More
Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat
March 15, 2016 10:56 AM EDTEvercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.
"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.
".. today's results suggests that while... More
Valeant Pharma (VRX) Conference Call Ends
March 15, 2016 10:13 AM EDTValeant Pharma (NYSE: VRX) brutal conference call ends. With shares down 36.7% traders will be looking for the stock to possibly rally later in the session.
... MoreValeant Pharma (VRX) Misses Dramatically Reduced Expectations - BMO
March 15, 2016 9:00 AM EDTBMO Capital analyst, Alex Arfaei, posted an earnings flash on Valeant Pharmaceuticals' (NYSE: VRX) miss and guide down. The call is ongoing and began at 8:00AM.
This morning, Valeant reported unaudited 4Q15 revenues of $2.78B, 1% above consensus of $2.75B. Gross margin of 75.6%... More
The Single Most Important Catalyst for Valeant Pharma (VRX) Near-Term...
March 15, 2016 8:15 AM EDTValeant Pharma (NYSE: VRX) is down 15% after posting unaudited fourth quarter result and disappointing 2016 guidance. However, according to Evecore ISI analyst Umer Raffat, the single most important catalyst for Valeant near-term is timing for covenants/10-K filing to avoid default .
The all-important date of a default is March 30th + 30 days, so April 29.
Covenant... More
Valeant Pharma (VRX) Misses Q4 EPS by 11c; Cuts Q1, FY16 Outlook
March 15, 2016 6:03 AM EDTValeant Pharma (NYSE: VRX) reported Q4 EPS of $2.50, $0.11 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.75 billion.
GUIDANCE:
Valeant Pharma sees Q1 2016 EPS of $1.30 - $1.55, versus prior guidance of $2.35 - $2.55 and the consensus of $2.63. Valeant Pharma sees Q1 2016 revenue of $2.3 - $2.4 billion, versus prior guidance of $2.8 - $3.1 billion and the consensus of $2.82 billion.
Valeant Pharma sees FY2016 EPS... More
